Article Text
Abstract
Introduction/Background Cervical and Endometrial Cancer are two gynecological neoplasms that include a common treatment which is the application of intracavitary brachytherapy. These two oncological entities are very frequent in developing countries such as Mexico and their suffering as well as their treatment derive in several acute and chronic complications such as sexual dysfunction. This study aims to describe the prevalence of sexual dysfunction in patients receiving intracavitary brachytherapy, as well as their psychosocial situation and the environment in which patients live their disease.
Methodology Patients with cervical cancer and endometrial carcinoma who were candidates for brachytherapy and who were free of acute pain at the time of the initial assessment were included. Each patient underwent a series of surveys that evaluate the presence of sexual dysfunction (SyDSF-AP questionnaire) and the psycho-social and demographic status of each patient.
Results The preliminary analysis of 55 patients treated with at least one application of brachytherapy for endometrial cancer (22%) or cervical cancer (78%) from a national reference cancer center is shown. With a mean age of 46 years, at least 40% of the patients had comorbidity and were overweight. Each patient received definitive treatment according to clinical stage. It was identified that 33% of the population had been victims of domestic violence and a predominance of symptoms associated with depression prior to treatment. The presence of sexual dysfunction was similar before and after brachytherapy treatment.
Conclusion Sexual dysfunction in gynecological neoplasms has been reported to be as high as 90% in this preliminary analysis; receiving brachytherapy did not significantly modify the prevalence before or after its application. It is important to identify the psychosocial factors in each patient‘s context to intervene in a timely manner and that each of the women with an oncologic pathology is evaluated in a comprehensive manner.